464 related articles for article (PubMed ID: 29192530)
21. Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis.
Wang X; Li Q; Sun S; Liang X; Li H; Huang J; Zhao T; Hu J; Liu J; Hu Z; Duan Y; He J
Medicine (Baltimore); 2022 Dec; 101(51):e31850. PubMed ID: 36595876
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Shaffer SR; Huang E; Patel S; Rubin DT
Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.
Stern S; Ward AJ; Saint-Laurent Thibault C; Camacho F; Rahme E; Naessens D; Aumais G; Bernard EJ; Bourdages R; Cohen A; Pare P; Dyrda P
J Med Econ; 2018 Jan; 21(1):27-37. PubMed ID: 28830258
[TBL] [Abstract][Full Text] [Related]
25. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
26. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
PLoS One; 2016; 11(8):e0160444. PubMed ID: 27494322
[TBL] [Abstract][Full Text] [Related]
28. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
29. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
30. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
32. The economics of adalimumab for ulcerative colitis.
Xie F
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
35. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
36. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
37. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China.
Zhou T; Sheng Y; Guan H; Meng R; Wang Z
Front Public Health; 2021; 9():704889. PubMed ID: 34490187
[No Abstract] [Full Text] [Related]
39. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
40. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.
Beilman CL; Thanh NX; Ung V; Ma C; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():5315798. PubMed ID: 27781203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]